Sudden cardiac death: etiologies, pathogenesis, and management.
Sudden death claims an estimated 350,000 lives per year in the United States. When death occurs within 1 hour of the onset of symptoms, 90% are the result of ventricular tachyarrhythmias. The majority of victims are middle-aged men with coronary artery disease, but in approximately 25%, sudden death is the presenting manifestation of their problem. In some populations, the detection of premature ventricular complexes (PVCs) by ambulatory monitoring is predictive of an increased risk of sudden death. However, the arrhythmia that best predicts this risk is unclear, and ambient arrhythmias are only a modest marker of this risk. Therapy to suppress asymptomatic PVCs has not been shown to be effective in preventing sudden death, and in some cases, lethal arrhythmias can be prevented without significant effects on ambient arrhythmias. Other risk markers such as depressed left ventricular function and the presence of low-amplitude, long-duration, late potentials recorded on a signal averaged electrocardiogram are more powerful predictors of risk than are PVCs. These latter findings in particular support the presence of areas of slow electrical conduction (a requirement for reentrant mechanism arrhythmias) and suggest that an abnormal electrical environment or "substrate" is the most important factor in this problem. The management of patients at risk for sudden death is controversial. While postinfarct survivors with arrhythmias constitute a population at increased risk, the absolute risk is only about 5% in the first year and has not been shown to be improved by conventional antiarrhythmic drugs. Small study size, arrhythmia variability, ill-defined end points, and proarrhythmia may partially explain this apparent lack of efficacy. The prophylactic use of antiarrhythmic drugs other than beta-blockers to prevent sudden death in asymptomatic populations at risk is therefore of unproven benefit. By contrast, patients who have survived a life-threatening arrhythmia unrelated to an acute myocardial infarction have an approximately 30% risk of recurrence in the following year. In these patients, the use of ambulatory monitoring to guide therapy is limited by the high incidence of false-negative responses (lethal arrhythmia recurrence despite ambient arrhythmia suppression) and the lack of frequent spontaneous arrhythmias in many patients. In this patient population, electrophysiological testing can be used to prognosticate recurrence and gain insight into arrhythmia mechanism, stability, and hemodynamic tolerance. The technique is also useful in guiding both pharmacological and nonpharmacological therapy.(ABSTRACT TRUNCATED AT 400 WORDS)
Kremers
M S
MS
University of Texas Southwestern Medical Center, Dallas.
Black
W H
WH
Wells
P J
PJ
D001145:Arrhythmias, Cardiac / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D003645:Death, Sudden / Q000209:etiology* / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006323:Heart Arrest / Q000209:etiology*; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors